G

Greenwich LifeSciences
D

GLSI

11.970
USD
-0.08
(-0.66%)
مغلق
حجم التداول
614
الربح لكل سهم
-1
العائد الربحي
-
P/E
-15
حجم السوق
157,341,496
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ATOS
    -0.04380
    (-5.21%)
    0.79610 USD
    B
    BNGO
    0.01500
    (0.28%)
    5.36500 USD
    N
    NNVC
    0.05500
    (3.82%)
    1.49500 USD
    S
    SLS
    -0.06000
    (-4.55%)
    1.26000 USD
    S
    SNDL
    0.00500
    (0.28%)
    1.77000 USD
    المزيد
الأخبار
المقالات

العنوان: Greenwich LifeSciences

القطاع: Healthcare
الصناعة: Biotechnology
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.